Growth financing CND Life Sciences has recently secured substantial growth funding from S-Curve Partners and other investors, signaling momentum and a need to scale operations, sales reach, and market expansion for the Syn-One Test platform.

Expanded reach With NIH grants and ongoing expansion plans tied to the Syn-One Test, there are opportunities to partner on clinical studies, payer discussions, and broader deployment in neurology clinics and reference laboratories.

Strategic collaboration Active research collaborations with biopharmaceutical companies indicate openness to co-development, data-sharing agreements, and joint offerings that could be complemented with additional diagnostic services or integrated reporting.

NGP market The Syn-One Test targets Parkinson’s disease, DLB, MSA, and PAf, suggesting sales opportunities in neurology practices, movement disorder centers, and essential tremor cohorts where predictive risk data add clinical value.

Digital infrastructure Existing tech stack and cloud-based operations (Google Cloud, Power BI, SAP, QuickBooks Online, Xero) create a foundation for scalable sales analytics, customer success dashboards, and streamlined contracting with clinics and hospital systems.